ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

NVCT vs GERN // RETURN ON INVESTED CAPITAL (ROIC)

Nuvectis Pharma Inc. (NASDAQ) VS. Geron Corporation (NASDAQ) • 15-METRIC TALLY: NVCT 3 — GERN 2
▲ RETURN ON INVESTED CAPITAL (ROIC) LEADER: GERN
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (NVCT VS. GERN) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC NVCT GERN SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) ACTIVE -35.00% -20.20% -14.80 GERN /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield -2.64% -18.27% +15.63 NVCT /fcf-yield <GO>
Operating Margin — — — TIE /operating-margins <GO>
Net Profit Margin — — — TIE /net-margins <GO>
Revenue Growth (YoY) — — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 2/9 3/9 -1.00 GERN /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 41.5 27.4 +14.10 NVCT /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $602.7M $574.6M $28.1M NVCT /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR NVCT REV GERN REV NVCT GROSS % GERN GROSS % NVCT FCF GERN FCF
FY 2025 $77.2M $192.0M — — -$16.0M -$111.0M
FY 2024 $55.6M $486.4M — — -$12.2M -$219.3M
FY 2023 $64.1M $237.0K — — -$16.0M -$167.7M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
NVCT // BETA —
GERN // BETA —